Status: Closed
Activation Date: 2009SEP04
Closing Date: 2013JUN13
Phase: III
Description: A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Eligibility: Advanced previously treated Non-Small Cell Lung Cancer
Objective: Progression free survival and Overall survival
Participation: Open to member centres
Lay Description: The purpose of this study is to find out whether it is better to receive a new drug PF-804 or better to receive no further treatment for lung cancer. To do this, two-thirds of the patients in this study will get PF-804 and the other third will receive a placebo (a substance that does not do anything).
Primary Publication Show
Other Publications Show
Inventory
Hide Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| LUNG | BR26 | 720 | 601 | 672 | 690 |
(Core size is 0.6 mm)
Hide
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| LUNG | BR26 | 720 | 2 | 52 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| LUNG | BR26 | 720 | 706 | 0 | 2 | 0 | 710 | 710 | 0 | 0 |